News

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum.

Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the acquired assets will be complementary to its gastric health portfolio and will let SSI offer a broader range of specialized products to US reference and hospital labs.

Financial and other terms of the deal were not disclosed.

Denmark-based SSID Group is a developer of infectious disease tests and antisera as well as reagents for gastric, respiratory, and blood-borne diseases and has facilities in California and Virginia. With the Gulf Coast Scientific acquisition, the company expects to generate revenues of DKK 850 million ($129.5 million) and deliver market-beating growth.

Nachum Shamir, SSID Group’s chair of the board of directors, said in a statement that the acquisition demonstrates a commitment to investing into and building the company.

“Our goal for the next few years is to rapidly grow SSID Group organically and through acquisitions,” Shamir said. “The USA is a key market, and we are excited to strengthen our position further with additional synergistic quality products in a new technological area.”

SSID Group CEO Christina Lindved added that customers in the US prefer to use a combination of rapid antigen-based screening and urea breath testing for H. pylori to provide testing for patients with differing sampling needs, and the acquisition allows the company to meet customer needs and serve more patients.

 

Read more here.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …